| Identification | Back Directory | [Name]
Biotin-PEG11-Mal | [CAS]
1646619-56-8 | [Synonyms]
1H-Thieno[3,4-d]imidazole-4-pentanamide, N-[39-(2,5-dihydro-2,5-dioxo-1H-pyrrol-1-yl)-37-oxo-3,6,9,12,15,18,21,24,27,30,33-undecaoxa-36-azanonatriacont-1-yl]hexahydro-2-oxo-, (3aS,4S,6aR)-
5-[(3aS,4S,6aR)-2-oxo-1,3,3a,4,6,6a-hexahydrothieno[3,4-d]imidazol-4-yl]-N-[2-[2-[2-[2-[2-[2-[2-[2-[2-[2-[2-[2-[3-(2,5-dioxopyrrol-1-yl)propanoylamino]ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethyl]pentanamide | [Molecular Formula]
C41H71N5O16S | [MDL Number]
MFCD11041107 | [MOL File]
1646619-56-8.mol | [Molecular Weight]
922.09 |
| Chemical Properties | Back Directory | [Boiling point ]
1025.2±65.0 °C(Predicted) | [density ]
1.201±0.06 g/cm3(Predicted) | [storage temp. ]
-20°C, stored under nitrogen | [form ]
Oil | [pka]
13.90±0.40(Predicted) | [color ]
Colorless to off-white |
| Hazard Information | Back Directory | [Uses]
Biotin-PEG11-Mal is a PEG-based PROTAC linker that can be used in the synthesis of PROTACs[1]. | [IC 50]
PEGs | [References]
[1] An S, et al. Small-molecule PROTACs: An emerging and promising approach for the development of targeted therapy drugs. EBioMedicine. 2018 Oct;36:553-562 DOI:10.1016/j.ebiom.2018.09.005 |
|
|